Axovant Gene Therapies Ltd (AXGT)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axovant Gene Therapies Ltd. ("Axovant" or "the Company") (NASDAQ: AXGT). The investigation concerns whether Axovant and certain of its officers and/or directors have violated federal securities laws.


On October 29, 2020, Axovant disclosed that manufacturing delays would potentially postpone the start of enrollment in the Company’s planned randomized, sham-controlled trial of AXO-Lenti-PD gene therapy for Parkinson’s disease, and that the trial seemed unlikely to enroll patients by the end of calendar year 2021.  On this news, Axovant’s stock price fell $1.52 per share, or 41.64%, to close at $2.13 per share on October 30, 2020.


If you are aware of any facts relating to this investigation, or purchased Axovant shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.